• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sab Biotherapeutics Inc (NQ: SABS )

    3.200 +0.330 (+11.50%)
    Streaming Delayed Price Updated: 3:49 PM EDT, Jul 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,544
    Open 3.040
    Bid (Size) 2.700 (1)
    Ask (Size) 3.300 (2)
    Prev. Close 2.870
    Today's Range 2.882 - 3.200
    52wk Range 0.4100 - 6.390
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    SAb Biotherapeutics Rebrands as SAB BIO
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +357.14%
    +357.14%
    1 Month
    -3.61%
    -3.61%
    3 Month
    -29.67%
    -29.67%
    6 Month
    -45.76%
    -45.76%
    1 Year
    +276.47%
    +276.47%

    More News

    Read More
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Departure of Chief Financial Officer
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Provides SAB-142 Trial Update
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at INNODIA Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Executive Leadership Change
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.